Non-vitamin K oral antagonist (NOAC) compared to vitamin K antagonist (VKA) in left ventricular thrombus.

Abstract

Thromboembolic events are serious left ventricular thrombus (LVT) complications. Despite the limitations of vitamin K antagonist (VKA) drugs, it continues to be the recommended oral anticoagulation for LVT. Recently, nonvitamin K oral antagonist (NOAC) has gained popularity as an off-labeled treatment for systemic embolism prevention in LVT. In this study, we aim to compare the outcomes (stroke and bleeding) of warfarin versus NOAC therapy in patients with LVT. This retrospective cohort study compares NOAC and VKA therapy in LVT patients. We enrolled 201 patients with an echocardiography-confirmed LVT from January 2018 to December 2022. Patients who received NOAC therapy (NOAC, <i>n</i> = 77) were compared to VKA patients (VKA, <i>n</i> = 124). The primary endpoint was a composite of stroke, minor and major bleeding. The median follow-up time was 17 months (25^th-75^th percentiles: 8-38). On unmatched analysis, both groups had no difference in major bleeding (log-rank, <i>P</i> = 0.61) and stroke (log-rank, <i>P</i> = 0.77). However, all bleeding events were higher with NOAC (log-rank, <i>P</i> = 0.01). On matched analysis, there was no difference between both groups in the overall bleeding events (<i>P</i> = 0.08), major bleeding (<i>P</i> = 0.57), and stroke (<i>P</i> = 0.66). Minor bleeding was significantly lower in the VKA group (<i>P</i> = 0.04). In patients with LVT, NOAC was as effective as VKA in stroke prevention without increasing the risk of major bleeding.